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Summary 
Neurons have evolved strategies to evade immune surveillance that include an inability to syn- 
thesize the heavy chain of the class I major histocompatibility complex (MHC), proteins that 
are necessary for cytotoxic T  lymphocyte (CTL)  recognition of target cells.  Multiple  viruses 
have taken advantage of the lack of CTL-mediated recognition and killing of neurons by estab- 
lishing persistent neuronal infections and thereby escaping attack by antiviral CTL. We have 
expressed a class I MHC molecule (D  b) in neurons oftransgenic mice using the neuron-specific 
enolase (NSE) promoter to determine the pathogenic consequences of CTL recognition ofvi- 
rally infected,  MHC-expressing central nervous system (CNS)  neurons.  The NSE-D  b trans- 
gene was  expressed in  H-2  b founder mice,  and  transgene-derived messenger RNA  was  de- 
tected by reverse transcriptase-polymerase chain reaction in transgenic brains from several lines. 
Purified primary neurons from transgenic but not from nontransgenic mice adhered to cover- 
slips coated with a conformation-dependent monoclonal antibody directed against the D b mol- 
ecule and presented viral peptide to CTL in an MHC-restricted manner, indicating that the D b 
molecule was expressed on transgenic neurons in a functional form. Transgenic mice infected 
with  the  neurotropic  lymphocytic  choriomeningitis  virus  (LCMV)  and  given  anti-LCMV, 
MHC-restricted CTL displayed a high morbidity and mortality when compared with controls 
receiving MHC-mismatched  CTL  or  expressing  alternative  transgenes,  After  CTL  transfer, 
transgenic  brains  showed  an increased nutnber  of CD8 +  cells  compared with  nontransgenic 
controls as well as an increased rate of clearance of infectious virus from the CNS. Additionally, 
an increase in blood-brain barrier permeability was detected during viral clearance in NSE-D  b 
transgenic mice and lasted several months  after clearance of virus from neurons.  In contrast, 
LCMV-infected, nontransgenic littermates and mice expressing other gene products from the 
NSE promoter showed no CNS disease,  no increased intraparenchymal CTL,  and no blood- 
brain barrier damage after the adoptive transfer of antiviral CTL. Our study indicates that viral 
infections and CTL-CNS interactions may induce blood-brain barrier disruptions and neuro- 
logic disease by a "hit-and-run" mechanism, triggering a cascade of  pathogenic events that pro- 
ceeds in the absence of continual viral stimulation. 
S 
everal properties unique  to the  central nervous system 
(CNS) 1 led to the concept that the CNS is an immune- 
privileged  site  (1,  2).  To  recognize  and  lyse  target  cells 
within  the brain  parenchyma, immune effector cells  must 
cross the blood-brain barrier,  a tightly packed wall of en- 
dothelia  that  separates  the  circulatory  system from  CNS 
cells.  While  nutrients  and  oxygen  either  diffuse  or  are 
transported across the  barrier,  the  passage of blood-borne 
Abbreviations used in this paper: aa, amino acid; CNS, central nervous sys- 
tem; LCMV, lymphocytic choriomeningitis virus; mRNA,  messenger 
1KNA; NP, nucleoprotein; NSE, neuron-specific  enolase. 
proteins  and  cells  (including  red  blood  cells  and  resting 
lymphocytes) into  the  brain is  restricted,  because of both 
the  fight junctions between the capillary endothelia and a 
lack of active cell transport by the endothelial  cells  them- 
selves  (for review see  references 3  and  4).  However,  the 
barrier does not isolate the parenchyma from activated im- 
mune cells;  activated T  lymphocytes and monocyte/mac- 
rophages traverse the intact blood-brain barrier and traffic 
through the brain (5-9). These infiltrating, activated T  cells 
are  restricted  from recognizing  CNS  targets,  however,  at 
least partly because of a paucity of cell surface molecules re- 
quired  for T  cell-target interaction.  Resident  cells  of the 
CNS normally express low to undetectable levels of both 
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glycoproteins present foreign (viral) proteins in the form of 
8-11  amino  acid  (aa)  peptides  to  the  T  cell  receptor  of 
CD8 +  cytotoxic  T  lymphocytes.  Neurons,  both  in  vivo 
(13-15)  and in vitro (12,  14,  16-18), do not express MHC 
class  I  molecules  and,  hence,  do  not  serve  as  targets  for 
CTL-mediated lysis. Multiple RNA  and DNA viruses, in- 
cluding members  of the  Herpes-,  Paramyxo-,  Rhabdo-,  Pi- 
coma-,  and Arenavirus  families, infect neurons  of the  CNS 
(for  review  see  references  19-21).  Viruses  from  each  of 
these families are able to establish latent or persistent infec- 
tions in CNS neurons, most likely because viral persistence 
in neurons through immune evasion is preferable to lysis by 
antiviral CTL of these essential and irreplaceable cells. 
Earlier studies began to characterize neuron-virus-CTL 
interactions  using  the  OBL-21  neuronal  cell  line  (14). 
These cells contain neurofilaments and show electrophysi- 
ologic  responses  consistent  with  neurons  (22),  although, 
unlike CNS neurons,  they are dividing cells. Like neurons 
in vivo, OBL-21  cells fail to express MHC  molecules, and, 
although  infected with  virus and  expressing viral proteins 
on  their  surfaces,  were  not  lysed by  antiviral  CTL  (14). 
However, after complementation of class I MHC  antigen- 
presenting capacity by transfection with a Db-encoding ret- 
roviral vector, infected OBL-21  cells were lysed by antivi- 
ral CTL (14). 
In  this  paper we  extend  these  in  vitro  observations  in 
vivo. First, transgenic mice that express a class I MHC  mol- 
ecule  on  CNS  neurons  were  established.  Second,  MHC- 
expressing  neurons  purified  from  such  transgenic  mice 
were  susceptible to lysis by virus-specific MHC-restricted 
CTL, whereas neurons from nontransgenic mice were not. 
CNS disease was induced in virally infected transgenic mice 
after  adoptive  transfer  of  virus-specific,  MHC-restricted 
CTL.  The  disease  lasted  for  several  months  after  CTL 
transfer and was associated with an increased number ofin- 
traparenchymal CD8 + cells and a chronic destabilization of 
the blood-brain barrier. 
Materials  and Methods 
Animals,  Cells, and Viruses.  C57BL/6 (H-2b), SJL (H-29, and 
BALB/cByJ (H-2  a) inbred mice were obtained from the closed 
breeding facility of The Scripps Research Institute (La JoUa, CA). 
Animals were maintained in conditions consistent with American 
Association for the Accreditation of Laboratory Animal Care reg- 
ulations throughout the course of the investigation. 
Lymphocytic  choriomeningitis  virus  (LCMV)  strain  Arm- 
strong CA  1371  clone  53b  (LCMV  ARM)  was  used  in  these 
studies. The origin, cloning and plaque purification of stock virus 
have been reported (23,  24). Virus was grown in baby hamster 
kidney  cells  and was  plaque  purified and  titered on  Vero  cell 
monolayers as  described (24).  BALB  clone 7  (H-2  a)  fibroblasts 
and Vero  cells  were  grown  in  MEM  supplemented with  10% 
heat-inactivated FCS,  1 mM r-glutamine,  104  U/ml penicillin, 
and 10 mg/ml streptomycin. MC57  (H-2  b) fibroblasts were cul- 
tured in  RPMI  1640  with  the  supplements listed above.  CTL 
clones restricted by H-2  b (clone NP18 recognizing nucleoprotein 
[NP] aa residues 396-404; 25) and H-2  a (clone HD8 recognizing 
NP aa residues 118-127; 26) were used. These clones were main- 
rained in culture as described (25). 
Persistent infection of mice  was  achieved by  inoculation of 
1,000  PFU of LCMV ARM intracerebrally into newborn mice 
within  18  h  of birth. Such mice carry infectious virus and viral 
nucleic acid in many cells,  including neurons,  throughout their 
lives (27). 
Cloning Procedures and Establishment of Transgenic Mice.  Stan- 
dard molecular techniques  (28,  29)  were used for the construc- 
tion of the NSE-D  b transgene. The NSE expression vector (30, 
31) was obtained from S. Forss-Petter, (The Scripps Research In- 
stitute) and the Mo/D  b clone (32) from R. Flavell, (Yale Univer- 
sity, New Haven, CT). Promoter-transgene junctions created by 
the subcloning were sequenced before microinjection. Fertilized 
oocytes were obtained from (C57B1/6  ￿  SJL) female mice. Puri- 
fication of  the transgene, preparation of  mice, microinjection, and 
embryo implantations were carried out as described (33-35). 
Transgenic mice were identified by tail biopsy and subsequent 
DNA isolation. 10 FLg of DNA was slot blotted onto filters (Ny- 
tran;  Schleicher &  Schuell, Inc., Keene, NH)  and probed with 
the SV40 sequence located at the 3'  end of the NSE expression 
cassette. 
Reverse Transcriptase-PCR (RT-PCR).  Brains  and  other  or- 
gans were removed from saline-perfused mice and were snap fro- 
zen in liquid nitrogen. The tissues were stored at -70~  before 
homogenization.  Tissues were  homogenized  using  a  Virtishear 
(Virtis Co., Inc., Gardiner, NY) for 30 s in 1 ml Tri-reagent/100 
mg  tissue  (Molecular Research  Center,  Inc.,  Cincinnati,  OH), 
and RNA was purified according to their recommended proto- 
col. 500 ng of total RNA was reverse transcribed by the random 
priming method,  using random  hexamers  (Pharmacia  Biotech, 
Inc.,  Piscataway,  NJ)  and  reverse  transcriptase  (GIBCO  BRL, 
Gaithersburg,  MD).  The  RNA-cDNA  duplex  was  then  sub- 
jected to 40 rounds of PCR (60~  annealing temperature; Taq I 
polymerase from  GIBCO  BRL),  using 20-mer oligonucleotide 
primers designed to amplify transgene specific sequences: A  =  5' 
GAGAT  CGACT  CTAGA  GGATC  3';  B  =  5'  GCGCT 
CTGGT TGTAG TAGCC 3'. The PCR products were visual- 
ized by ethidium bromide intercalation on a 1% agarose gel. 
Hippocampal Neuron Cultures and Protein Detection.  Embryonic 
mice  (day  16-18)  were  used for  the  preparation of dissociated 
hippocampal neuron  cultures following the protocol of Banker 
and Goslin (36)  with minor modifications (37;  Rall, G. F., un- 
published results).  Briefly, hippocampi were dissected from em- 
bryos and placed in  ice-cold plating medium  (DMEM  supple- 
mented with 10% fetal bovine serum, 104 U/ml penicillin, and 10 
mg/ml streptomycin). The tissues were washed three times with 
ice-cold PBS and digested with trypsin-EDTA (Sigma Chemical 
Co., St. Louis, MO) at 37~  for 15 rain. The tissue was washed 
twice with plating medium, mechanically dissociated with fire- 
polished pipettes, and passed through a cell strainer (Falcon Lab- 
ware, Oxnard, CA) to obtain a single-cell  suspension.  The neurons 
were spun at 150 g for 7 rain onto a serum cushion, resuspended, 
counted,  and plated onto  either poly-L-lysine (Sigma Chemical 
Co.)  or  antibody-coated,  acid-washed,  round  glass coverslips 
(Carolina Biological Supply Co., Burlington, NC) at a density of 
500 cells/mm  2. 
Individual coverslips were incubated with affinity-purified goat 
anti-mouse IgG (Cappel Laboratories, Cochranville, PA; 10 p~g/ 
slip) for 4 h, washed with PBS and then coated with rnAbs spe- 
cific for either the D b class I MHC molecule (B22. 249.R1, 1:500; 
Cedarlane Laboratories Ltd., Homby, Ontario, Canada) or to the 
L  a class I MHC molecule (30-5-7S, 1:500;  Cedarlane Laborato- 
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placed in a humidified incubator overnight, and, immediately be- 
fore neuron plating, the antibody was aspirated and the slips were 
washed once with PBS, pH 7.4. 
4  h  after the  neurons were  added to  the  coverslips,  the  slips 
were placed on top of a confluent primary astrocyte feeder layer 
(40),  in serum-free neurobasal medium (GIBCO BRL)  supple- 
mented with growth factors  (B27 additive; GIBCO BRL).  The 
cells were maintained at 37~  in 5% CO2. 
In  Vitro Killing Assay.  Neurons  cultured  in vitro  for  48  h 
were either untreated or were coated with peptides representing 
LCMV CTL epitopes restricted by either H-2  b (NP aa 396-404: 
NH2-FQPQNGQFI-COOH)  or H-2  d (NP  aa  118-127:  NH2- 
SERPQASGVG-COOH)  at a concentration of 40 beg/2  ￿  104 
targets 1 h before the addition of CTL. H-2  b- or H-2a-restricted 
CTL clones were  then added to the cultures at a  1:1  ratio,  and 
they  were  allowed  to  incubate for  6  h.  After  removal  of the 
clones and debris by successive PBS  washes,  the  neurons were 
fixed with 2% paraformaldehyde and were  counterstained with 
hematoxylin.  10 random fields  were  counted per slide, and the 
results were confirmed in three independent experiments. MC57 
(H-2  b) and BALB c17 (H-2  a) fibroblasts served as controls. 
Adoptive  Transfer  of  Memory  CTL  into Persistently Infected 
Mice.  Adoptive  transfer  of antiviral CTL  into  persistently in- 
fected mice has been described (41).  The memory cytotoxic ef- 
fector cells transferred were obtained from normal adult C57BI/6 
or SJL mice infected 60-120 d earlier by intraperitoneal inocula- 
tion of 2 X  10  s PFU of LCMV. Spleens were removed and disso- 
ciated, and a single-cell suspension was prepared and cultured in 
24-well  plates  with  syngeneic  LCMV-infected  and  irradiated 
peritoneal macrophages  (as stimulators) and syngeneic irradiated 
spleen ceils  (as feeder cells).  Adherent lymphocytes (secondaries) 
were expanded three times on infected, irradiated stimulator cells 
before  transfer into age-matched  (6-13-wk-old)  persistently in- 
fected mice and nontransgenic controls. 
Transgenic  and  nontransgenic mice  (H-2  b)  were  bred  with 
nontransgenic SJL  mice  (H-2  s)  to  generate H-2  bxs mice for the 
adoptive  transfer experiments.  The  progeny  of such  breedings 
was infected with LCMV (103 PFU) within 24 h  of birth to es- 
tablish persistent infections. The presence of virus in these mice 
(between 4 and 8 wk) was determined before the adoptive trans- 
fer by serum plaque assay. 24 h before the transfer of 5 X  106 sec- 
ondary CTL intraperitoneally, mice were irradiated with 400 rad 
to  accommodate  the  adoptively transferred cells.  The  health of 
the  animals was  monitored daily from  1 to  30  d  after adoptive 
transfer and weekly thereafter, and evaluated on a four-level scale: 
1, healthy and indistinguishable from uninfected normal mice; 2, 
fur  slightly ruffled,  posture  hunched,  eyes  partially closed,  re- 
duced mobility; 3, ruffled, hunched, and tremulous, eyes mucous 
filled and closed, significant motor impairment; 4, dead. 
Viral titers in serum were monitored 6, 15, 60, and 120 d after 
adoptive transfer, and mice from experimental and control groups 
were killed at  15 and 60 d after adoptive transfer for histological 
studies. 
Detection of CD8  + Lymphocytes within Brain Sections.  /Mice  were 
deeply anesthetized with a 3.8% solution of chloral hydrate and 
were perfused with normal saline. Brains were rapidly removed, 
quick frozen in a dry ice/isopentane bath, and stored at  -70~ 
10-1am horizontal sections were cut and fixed in 95% ethanol for 
15 min at -20~  were blocked with avidin-biotin (Vector Lab- 
oratories,  Inc., Burlingame, CA),  and were  incubated for  1.5 h 
with mAbs to the murine CD8 molecule (CD8a and Ly3, diluted 
1:50; Pharmingen, San Diego, CA). After washing, sections were 
incubated with biotinylated secondary antibodies, followed by an 
avidin-biotin reaction (ABC Elite; Vector Laboratories, Inc.) and 
a color reaction using diaminobenzidene and hydrogen peroxide. 
Sections were lightly counterstained with hematoxylin and were 
mounted with Aquamount (Lemer Laboratories, New Haven, CT). 
The median values of the number of CD8 + lymphocytes per 
brain section within a given group were calculated. At least four 
horizontal sections were evaluated per mouse brain. 
Blood-Brain  Barrier Permeability.  Mice  were  deeply anesthe- 
tized with a 3.8% solution of chloral hydrate. 2 ml of a 2% Evans 
blue solution in PBS was infused transcardially over a  l-rain pe- 
riod. 3 rain later, mice were perfused with 4% paraformaldehyde 
in PBS, and brains were removed and stored in 0.2% paraformal- 
dehyde in PBS. 
Results 
The Class I MHC Molecule,  D ~, Is Expressed  in Neurons of 
Transgenic Mice.  Transgenic  mice  with  neuronal  expres- 
sion of the  class I  MHC  molecule D b were  established by 
injection of oocytes with a  minigene containing the com- 
plete  D b  coding sequence  under  the  control  of the  NSE 
promoter  (Fig.  1).  The D b minigene (40)  was  cloned into 
the BamHI restriction site within exon 2  of the NSE  cas- 
sette  (Fig.  1),  and  the  resulting plasmid was  characterized 
by restriction  analysis and  sequencing of promoter-trans- 
gene junctions. The linearized, gel-purified NSE-D b trans- 
gene was then microinjected into ~200  (C57B1/6  ￿  SJL)F2 
one-cell stage embryos. 
From  this  microinjection,  42  mice  were  born,  12  of 
which contained the transgene. Five of these founder mice 
were selected for breeding and were back-crossed onto the 
C57B1/6  background.  After  three  back-crosses,  the  CTL 
response within these mice was completely restricted to the 
H-2  b haplotype  as determined by chromium release assays 
(data not shown). 
Tissue  expression  of  the  NSE-D b  messenger  RNA 
(mRNA)  was  analyzed  by  RT-PCR  on  RNA  isolated 
from  transgenic  and  nontransgenic  mouse  tissues  (brain, 
el  e2  .,~1 
I 5'  REGULATORY  SEQ~.CE  ~~  NSE CASSETTE 
l kb~  poly  A~  ' 
I  '  ,t o b  MIN,QENE 
el I1  e2  i2  e 3-8  3' UTR 
500 bp 
Figure  1.  Structure  of the NSE-D  b fusion gene.  The NSE-D  b con- 
struct consists of 2.8 kb ofS' NSE regulatory sequence, NSE exon 1 and 
intron 1, and 15 bp ofNSE exon 2 plus polylinker. The D  b minigene in- 
cludes all 8 exons and the first two introns of the murine D b gene. Poly- 
adenylation signals are provided by 3' untranslated sequences (UTR) of 
the D b minigene. SV40 sequence at the 3' end of the construct facilitates 
identification of transgenic mice by slot blot analysis  ofgenomic DNA. e, 
exon; i, intron. 
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were removed from transgenic (+)  and nontransgenic (-)  mice. Total 
RNA was extracted and subjected to RT-PCR as described in Materials 
and Methods, Primers A and B were used to amplify transgene-specific 
mRNA. The primer pair was designed to differentiate spliced and un- 
spliced templates by size; the primers span intron 1 of the D  b sequence, so 
that the predicted PCR product derived from spliced mRNA is 180 bp 
smaller than the product derived from either unspliced RNA or residual 
DNA in the preparation (Fig. 2 13). Spliced mRNA (as a 320-bp PCR 
product) was detected in each of the five transgenic lines, and, in some 
cases, a PCR product corresponding  to DNA or unspliced RNA (500 bp) 
was seen (lines 23 and 29). No PCR product was amphfied in nontrans- 
genic mice (line 21-).  Results obtained in three mice per group are 
shown. 
spleen,  kidney,  pancreas,  liver,  testes,  gut,  thymus,  lung, 
heart,  and optic and sciatic nerves).  Total brain RNA  iso- 
lated from mice of six transgenic lines (7, 9, 11, 21, 23, and 
29)  contained  transgene-derived  mRNA,  whereas  brain 
RNA  from  nontransgenic  littermates  did  not  (Fig.  2  A). 
Transgenic lines 9  (data not shown)  and  11  were  used for 
subsequent  experiments.  No spliced NSE-D  b mRNA  was 
detected in other organs except for in the testes  of line 29 
(data not shown).  Line 29 was not used for further experi- 
ments. 
Total  RNA  purified  from primary  astrocyte/microglial 
cultures  derived  from transgenic  neonatal  mice  of lines  9 
and  11  were also analyzed by the RT-PCR  approach.  No 
RNA  PCR  product corresponding to  the  NSE-D  b trans- 
gene was detected in these cultures (data not shown). 
The NSE-D  b expression at the protein level was too low 
to be detected by immunostaining of tissue sections. How- 
ever,  neuronal  expression  of D b protein was demonstrated 
by culturing primary embryonic hippocampal neurons and 
testing their ability to grow on glass  coverslips coated with 
an mAb specific for either D b or for a heterologous MHC 
molecule  (anti-Ld).  Neurons  from transgenic  (Db-express- 
ing)  mice  adhered  to  anti-D b-,  but  not to  anti-L&coated 
coverslips  (Fig.  3).  Nontransgenic  neurons  did  not attach 
to  either  type  of  coverslip,  confirming  the  absence  of 
MHC  class  I  on their surface.  Notably, the antibody used, 
B.22.249,  is  conformation dependent  (32).  Therefore,  the 
D b  molecule  is  expressed  in  a  conformationally  correct 
form on the surface oftransgenic neurons. 
The  Transgene-derived  D b  Molecule  Conferred  CTL  Rec- 
ognition and Lysability  to CNS Neurons In  Vitro.  We next de- 
termined whether transgenic neurons could present antigen 
and  serve  as  targets  for CTL-mediated  lysis  in  a  neuronal 
survival assay.  Primary neurons do not take up S~Cr; there- 
fore,  instead  of standard chromium release  assays,  an alter- 
native  assay  was used.  Transgenic  and nontransgenic  neu- 
rons were incubated with peptides encoding LCMV-specific 
epitopes that are restricted by either H-2  b or H-2  d (25, 26, 
35).  Peptide-coated  neurons  were  reacted  with  specific 
anti-LCMV H-2  b- or H-2&restricted CTL clones, and the 
number of viable neurons was determined after a 6-h incu- 
bation.  Db-expressing  neurons  incubated  with  H-2  b- 
restricted viral peptide and a matched CTL clone showed a 
significant  reduction  (73%)  in  cell  viability  (P  <  0.05), 
whereas nontransgenic neurons did not (Fig. 4). These data 
were reproducible in three independent experiments. 
Persistently  Infected,  Transgenic Mice Developed CNS Disease 
after  Adoptive  Transfer  of LCMV-specific  Db-restricted  CTL. 
NSE-Db-expressing  mice  were  maintained  in  a  specific 
pathogen-free facility. No differences in appearance, fecun- 
dity, or life span were noted between uninfected transgenic 
animals  and  nontransgenic  littermate  controls  (data  not 
shown). 
To  determine  the  antigen-presenting  capacity of trans- 
genic neurons in vivo and the consequences of their inter- 
action with Db-restricted CTL, mice were infected as neo- 
nates with LCMV. In this persistent infection, most tissues, 
including  the  CNS,  liver,  spleen,  and  kidney,  contain 
LCMV; within  the  CNS,  the neuron is the  only cell type 
infected  (42,  43).  Adoptive  transfer  of  virus-specific, 
MHC-restricted  CTL  (41,  44)  results  in  CTL-mediated 
clearance  of LCMV from all sites,  other than  neurons and 
renal glomeruli, within 10-30 d after transfer. The eventual 
elimination of  virus and viral nucleic acid from neurons oc- 
curs over a longer period (60-120 d after adoptive transfer) 
and  does  not involve  obvious infiltration  of the brain  pa- 
renchyma  (41).  The  mechanism  of viral  clearance  from 
nontransgenic, persistently infected brains is not completely 
understood, but does not seem to occur via classical  CTL- 
target cell interactions. 
NSE-D  b transgenic  mice,  NSE-amyloid precursor pro- 
tein (APP) transgenic mice (expressing APP as a non-MHC 
transgenic  control; 31), and nontransgenic littermates were 
infected with LCMV at birth. Each of these groups of mice 
was generated by breeding an H-2  b transgenic parent with 
a nontransgenic  SJL (H-29  mouse,  resulting in H-2  bX~ off- 
spring.  Secondary immune  T  lymphocytes raised  in  H-2  b 
or H-2  ~  mice were then adoptively transferred into the per- 
sistently infected H-2  bx~ animals. This experiment was based 
on  the  following  rationale:  both  H-2  b  and  H-2  ~ anti- 
LCMV  CTL  could  recognize  virally  infected  cells  in  pe- 
ripheral  tissues  of persistently  infected  H-2  bx~  mice,  but 
only H-2  b anti-LCMV CTL would recognize viral antigen 
complexed  with  the  D b molecule  on  NSE-D  b transgenic 
neurons.  Thus,  if mice  became  sick  or  died  as  a  conse- 
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from transgenic and nontransgenic litters were plated onto coverslips coated with mAbs to either D  b (B22.249) or L  a (30-5-7S) as described in Materials 
and Methods. Photographs  were taken 48 h after plating. Staining with antibody against the neuronal marker, microtubule-associated  protein 2 indicated 
that >95% of  the adherent cells were neurons. 
quence of CTL interactions with the D b expressed on neu- 
rons,  this  should be seen only in NSE-D  b transgenic  mice 
receiving the H-2b-restricted CTL (Fig. 5). 
Animal  health  was  monitored  daily  and  independently 
by at least two investigators after adoptive transfer of CTL. 
The genetic profile of the mice and the CTL that they re- 
ceived were unknown to the observers to avoid bias.  Per- 
sistently infected mice appeared healthy before the adoptive 
transfer.  5-15 d  after transfer,  when CTL are killing virally 
infected MHC-expressing  cells  in  peripheral  tissues  (liver, 
spleen, kidney, etc.)  (41), some mice showed mild to mod- 
erate illness  (clinical levels 2-3) in all experimental  groups. 
The combined results (Table  1) of three independent adop- 
tive transfer experiments using a minimum of  four mice per 
experimental  group  revealed  the  following:  (a)  NSE-D  b 
transgenic mice exposed to H-2  b CTL showed significantly 
higher  morbidity  and  mortality  than  NSE-APP  or  non- 
transgenic  controls  receiving  similar  immunotherapy;  (b) 
NSE-D  b mice had a higher morbidity and mortality when 
given H-2  b CTL compared with H-2  + CTL, whereas H-2  b 
and  H-2  s CTL had  a  similar  effect in  the  control groups; 
and  (c)  NSE-D  b mice  that  survived  the  initial  15-d  viral 
clearance period remained sick throughout the observation 
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period  (clinical stages 2-3), whereas  control mice returned 
to clinical stage  1 after viral clearance. 
NSE-lY'  Transgenic Mice Receiving Adoptive  CTL  Therapy 
Showed Increased Numbers of CD8  + Lymphocytes  in the CNS 
Parenchyma and Accelerated Viral Clearance.  Brains were re- 
moved from mice at various time points after adoptive trans- 
fer and stained with mAbs to murine CD8 to compare the 
number  of infiltrating  CTL within  the  brains  of NSE-D  b 
transgenic versus control mice. Photomicrographs of repre- 
sentative routine brains are shown in Fig. 6, and a quantita- 
tive  summary  is  shown  in  Table  2.  Uninfected  NSE-D  b 
transgenic  brains  contained  rare  CTL  (Fig.  6  A;  Table  2, 
group A), suggesting that the expression of D b on neurons 
per  se  is  not  sufficient  to  recruit  T  cells  into  the  paren- 
chyma. The CD8 §  CTL found within the brains of  persis- 
tently infected mice were distributed uniformly throughout 
the  parenchyma,  and  both  transgenic  and  nontransgenic 
mice killed at various ages after neonatal  LCMV infection 
contained  similar  numbers  of intraparenchymal  CD8 §  T 
cells (Fig. 6  B; Table 2, groups B  and C).  In contrast,  15 d 
after  adoptive  transfer  of Db-restricted  anti-LCMV  CTL, 
there  was  a  marked  increase  in  the  number  of CD8 +  T 
cells  within  brains  of persistently  infected,  NSE-D  b trans- Figure 4.  Lysis  of Db-expressing primary  neurons  coated with appro- 
priate  viral peptide by Db-restricted  LCMV-specific  CTL. Primary neu- 
rons were incubated  for 1 h with peptides  encoding  epitopes for LCMV 
restricted  by either H-2  b (viral NP,  aa 396-404)  or H-2  d (NP,  aa  118- 
127) or with no peptide (- -). One hour after peptide addition,  H-2  b- or 
H-2a-restricted  antiviral CTL were added  to  the  cultures.  5-6  h  later, 
neurons  were fixed,  stained,  and  counted as described in Materials and 
Methods.  Numbers of neurons  in cultures incubated with no peptide and 
H-2  d CTL were arbitrarily  defined  as  100%. Data points  represent  the 
number of remaining  neurons  expressed as a percentage  of this control; 
error bars indicate SD. Similar results were obtained independently  in two 
additional  experiments  (data not shown).  * P values <0.05  by the Stu- 
dent's  t test, 
genic  mice  (Fig.  6  C;  Table  2,  group  D),  which  was  not 
seen  in  nontransgenic  controls  receiving similar immuno- 
therapy  (Fig. 6  D; Table 2,  group E).  Interestingly,  in areas 
densely  populated  with  LCMV-infected  neurons,  such  as 
the hippocampus  and the Purkinje  cell layer of the cerebel- 
lum, no obvious signs of neuronal  dropout were seen,  sug- 
gesting  that  infected  neurons  were  not  lysed by  CTL.  By 
day  40,  the  number  of CTL  in  the  brains  of transgenic 
Figure 5.  Rationale of the adoptive transfer protocol.  See text for de- 
scription. 
mice  had  decreased  (Fig.  6  E;  Table  2,  group  F).  Similar 
findings  were  obtained  in  at  least  three  mice  per  experi- 
mental group. 
Brain tissues taken from mice  15  and 40 d  after adoptive 
transfer  were  also  plaque  assayed  to  assess  the  effect of the 
neuronal  MHC  expression  on  the  clearance  of virus  from 
transgenic  brains.  While virus was  still present  in brains  of 
nontransgenic  control mice  15  d  after adoptive transfer,  vi- 
rus was no longer detectable at this time point in transgenic 
brains  receiving the  H-2  b secondary  lymphocytes  (Fig.  7). 
Notably,  despite  an  accelerated  viral  clearance,  transgenic 
mice remained sick for up to 120 d  after the adoptive trans- 
fer. 
The Increased Sickness of NSE-D  b Transgenic Mice Correlated 
with a Chronic Disruption  ~  the Blood-Brain Barrier.  To  de- 
termine whether the increased number of CTL in the CNS 
Table  1.  Occurrence  of Sickness and Death in NSE-D  a, NSE-APP, and Nontransgenic Persistently Infected Mice 
Receiving H-2  ~  or H-2~restricted Antiviral  CTL* 
Injury after adoptive transfer in days (in %) 
Day 5-15  Day 15-60  Day 60-120 
CTL 
Transgene  Mice  MHC  Sickness  Death  Sickness  Death  Sickness  Death 
n 
NSE-D  b, line 9  18  H-2  b  100  33  85  0  69  0 
NSE-D  b, line 9  8  H-2  ~  50  12  14  0  0  I) 
NSE-D  b, line 11  14  H-2  b  93  43  78  0  88  0 
NSE-D  b, line 11  10  H-2  ~  25  0  11  0  11  0 
NSE-APP and  52  H-2  b  40  8  4  0  10  6 
Nontransgenic  15  H-2  ~  47  7  12  0  14  0 
* 5 ￿  106 CTL were transferred  into persistently  infected H-2  TM NSE-D  t', NSE-APP, or nontransgenic  mice. Health was monitored daily, and ac- 
cumulated sickness and death measurements  are presented as the percentage of the total number of animals in each group. 
1206  CTL Class I MHC-expressing Neuron Interactions In Vivo Figure  6.  Increased number of CD8 +  cells in brains of transgenic, persistently infected mice after adoptive transfer of H-2b-restricted anti-LCMV 
CTL. Sections ofcaudate (A-D) or cerebellum (E) were stained for the presence ofCD8 § lymphocytes as described in Materials and Methods, and were 
counterstained with hematoxylin. (A)  Uninfected NSE-D  b transgenic mouse, no CTL given; (B) persistently infected NSE-D  b mouse, no CTL given; 
(C) persistently infected, NSE-D  b transgenic mouse, day 15 after adoptive transfer of H-2  b secondaries; (D) persistently infected, nontransgenic mouse, 
day 15 after adoptive transfer of  H-2  b secondaries; (E) persistently infected, NSE-D b transgenic mouse, day 40 after adoptive transfer of H-2  b secondaries. 
￿  100. 
o  i 
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Figure  7.  Clearance of infectious virus from brains of transgenic and 
control  mice.  Brains of persistently infected NSE-D  b  or  control  (non- 
transgenic or NSE-APP)  mice were  removed 15 or 40 d  after adoptive 
transfer of H-2  b CTL, weighed, homogenized, and analyzed for the pres- 
ence of infectious virus by plaque assay. At least four animals per group 
were evaluated. Results represent means +  SD. 
Figure  8.  Abnormal permeability of the blood-brain barrier in persis- 
tently infected NSE-D  b mice after adoptive transfer of H-2  b LCMV-spe- 
cific CTL. Persistently infected mice were injected with Evans blue and 
peffused  as  described  in  Materials  and  Methods.  (A)  Nontransgenic 
mouse,  no  CTL  given;  (B)  persistently  infected  NSE-D  b  transgenic 
mouse given H-2' antiviral  CTL  120  d  previously;  (C)  persistently in- 
fected, nontransgenic mouse given H-2  b CTL and showing signs of sick- 
ness after 15 d after transfer; (D and E) persistently infected NSE-D  b mice 
given H-2  b CTL 120 d previously. 
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barrier,  mice were injected with Evans blue,  a dye which 
binds to serum proteins and is excluded from the brain pa- 
renchyma  by  the  normal  blood-brain  barrier.  In  persis- 
tently infected NSE-D  b transgenic mice, leakage of the dye 
into the brain parenchyma was observed as early as  15  d 
(n  =  4)  (data not shown) and as late as 120 d  (n =  5) after 
adoptive transfer of H-2  b restricted CTL (Fig.  8; Table 3). 
These  results  indicate  a  prolonged abnormal permeability 
of the blood-brain barrier, which persisted in the absence 
of viral antigen. Subtle differences in the pattern of perme- 
ability changes could be related to variations in the distri- 
bution or activity of the infiltrating lymphocytes. 
By  contrast,  no  other  group  of mice,  including  tran- 
siently sick nontransgenic mice killed 9 d after CTL admin- 
istration,  showed  any abnormality in  the  permeability of 
the blood-brain barrier (Table 3; Fig. 8). 
Discussion 
The current study revealed a number of novel findings. 
The expression of class I MHC glycoproteins in neurons of 
NSE-D  b transgenic mice had no deleterious effects on the 
health,  fecundity,  or life  span  of uninfected  mice.  MHC 
class [-expressing hippocampal neurons of transgenic mice 
presented  exogenous viral peptide  to  H-2-matched CTL 
in vitro, resulting in neuronal lysis.  In vivo interactions of 
antiviral H-2b-restricted CTL with Db-expressing neurons 
in mice persistently infected with LCMV resulted in signif- 
icant morbidity and mortality. Disease induced in the trans- 
genic mice was associated with an increase in the number 
of CD8 §  T  lymphocytes within the brain parenchyma, an 
increased rate of clearance of infectious virus from infected 
neurons,  and an increased permeability of the blood-brain 
barrier that continued for several months after the adoptive 
transfer of CTL and  after the  virus was  cleared from in- 
fected neurons. Although virus was cleared from Db-expres- 
sing neurons by 15 d after adoptive transfer, no obvious ly- 
sis of neuronal cells was observed. 
Our  in  vitro  findings  in  transgenic  primary embryonic 
neurons  confirm and  extend  previous  results  obtained  in 
OBL-21  neuronal  cells  (14,  17).  In  those  studies  it  was 
shown that OBL-21 cells were unable to present viral anti- 
gen to  CTL because of a paucity of class I  MHC on the 
OBL-21  cell surface.  Molecular  complementation with  a 
retrovirally expressed class I MHC molecule made infected 
OBL-21  cells  recognizable  and  lysable by antiviral  CTL. 
Although  OBL-21  cells  share  many  characteristics  with 
neuronal cells (e.g., expression ofneurofilaments, NSE, and 
voltage-dependent  potassium  channels;  22),  they,  unlike 
primary neurons, are dividing, transformed cells that grow 
in the presence of serum. 
Expressing D b MHC class I proteins in neuronal cells via 
transgenic technology and panning with mAb to D b in the 
current study allowed the in vitro analysis  of primary neu- 
ronal  cell-virus-CTL interactions.  As  these  primary neu- 
rons do not divide in culture and are grown in the absence 
of serum, they resemble differentiated neurons in the intact 
CNS  more  closely than  OBL-21  cells.  When  transgenic 
Db-expressing primary neurons were pulsed with viral pep- 
tide  or infected with virus  (Rail,  G.,  and M.  B.  A.  Old- 
stone,  unpublished  results)  and  challenged  with  MHC- 
matched  antiviral  CTL,  they  were  recognized  and  lysed, 
whereas primary neurons  from nontransgenic  mice under 
similar conditions  were  not.  Thus,  expression of a  class  I 
MHC molecule on primary neurons in vitro was sufficient 
to result in lysis by appropriate CTL. 
Interestingly, we  did  not  find  evidence  of CTL-medi- 
ated lysis  of neurons  in brains  of transgenic  mice, despite 
the  presence  of  intraparenchymal  CTL  and  rapid  viral 
clearance from the transgenic CNS. However, it should be 
noted that this study was not designed to accurately quanti- 
tate neuronal  counts and that a subtle dropout of neurons 
may have  occurred.  Nevertheless,  neurons  of the  hippo- 
campus and Purkinje  cell layer of the cerebellum are uni- 
formly infected by LCMV in vivo (41,  42);  yet at no time 
after adoptive transfer,  in  no  animal,  regardless  of health, 
were morphological changes consistent with  cell lysis ob- 
served in these regions. Thus, while transgenic neurons ex- 
pressing  the  correct  viral  peptide  bound  to  a  transgenic 
MHC  molecule were  suitable  CTL targets in  vitro,  such 
neurons did not appear to be effectively lysed in vivo. This 
observation may be due  to  a  restricted number of CD8 § 
CTL within the brain, which limits the cytotoxic effect of 
these cells. We believe this possibility is unlikely, however, 
given the rapid rate of viral clearance and blood-brain bar- 
rier damage within transgenic brains. 
Alternatively, one might consider that, while these neu- 
rons express the transgene in vitro, they may not in vivo, as 
no direct evidence  (e.g.,  immunohistochemical identifica- 
tion of the transgene product in brain sections) is provided. 
We feel that our inability to detect the class l molecule in 
brain sections was due to technical problems regarding the 
difficulty  of  immunostaining  within  the  brain,  coupled 
with the lack of a suitable, high-affinity antibody, and not 
due  to  the  absence  of expression  in  vivo.  The  adoptive 
transfer experiments provide strong evidence for functional 
protein expression in vivo: three groups of mice (NSE-D  b, 
NSE-APP, and nontransgenic littermates), two lines of the 
NSE-D  b mice (lines  9 and  11),  and two different immune 
lymphocyte haplotypes (b and s) were used to demonstrate 
a selective effect of H-2  b antiviral lymphocytes on virally 
infected H-2  b transgenic neuronal targets. Because only the 
combination  of mice  expressing  the  D b  molecule  with 
MHC-matched  H-2  b  immune  lymphocytes  resulted  in 
pathological conditions  (increased intraparenchymal CTL, 
increased blood-brain barrier permeability, prolonged sick- 
ness), functional expression of the class I MHC transgene in 
neurons is the most plausible explanation for these data. 
How these CTL exert their virucidal, but not cytocidal, 
effects in vivo is not known.  It is conceivable that factors 
released  from  neurons  or  glial  cells  interfere  with  lytic 
CTL-neuronal  interactions  contributing  to  the  relatively 
immunosuppressive/immune-privileged  microenvironment 
of the CNS, and that such factors interfere with the CTL- 
mediated cytolysis of vitally infected neurons.  Isolation of 
1208  CTL Class I MHC-expressing  Neuron Interactions In Vivo Table 2.  Accumulation of CD8 + T Cells Present in Brains of Mice Receiving Adoptive  Transfer of Immune Lymphocytes* 
Median number of 
intraparenchymal 
Adoptive transfer of  CD8 + T cells$ 
H-2  b anti-LCMV CTL 
Group  Mice  Virus  Transgene  (day observed)  Median  Range 
n 
A  3  -  +  -  12  (0-17) 
B  4  +  -  -  48  (19-82) 
C  4  +  +  -  55  (14-89) 
D  5  +  +  +  (15)  124  (48-211) 
E  4  +  -  +  (15)  62  (23-77) 
F  4  +  +  +  (40)  51  (15-69) 
*Persistendy infected (groups B-F) or uninfected (group A) NSE=D  b transgenic (groups A, C, D, and F) or nontrausgenic (groups B and E) mice 
were given either H-2b-restricted antiviral CTL (groups D-F) or no CTL (groups A-C). Brains were examined immunohistochemically  for the 
presence ofCD8 + T cells at either 15 (groups D and E) or 40 (group F) d after transfer as described in Materials and Methods. 
*Values given represent the median number of CD8 § positive cells found/horizontal brain section (determined from four sections per mouse, 
three-five mice per group). 
Table 3.  Increase  in Transgenic Mouse Blood-Brain Barrier Permeability Is Dictated by Expression of the Transgene 
in Virally Infected Mice Given Haplotype-matched Antiviral  CTL* 
Experimental model  Result 
Neurons expressing in vivo 
MHC class I  LCMV 
Adoptive transfer 
of Db-restricted, 
LCMV= specific CTL 
Percent incident of 
increased blood-brain 
barrier permeability 
+  +  +  100 (5/5) 
+  -  -  o  (0/5) 
+  -  +  0 (0/3) 
+  +  -  0 (0/4) 
-  +  +  o  (0/5) 
-  +  -  0  (0/5) 
*Persistently  infected (+) or uninfected (-) NSE-D  b transgenic (+) or nontransgenic (-) mice were given Db-restricted  antiviral CTL 120 d before 
blood-brain barrier assessment. Permeability  was determined by entry of Evans blue into the parenchyma. The percentages of mice with Evans blue 
infiltration are given, with the total number of mice per group in parentheses. 
neurons from this environment by in vitro culture may re- 
move them from these factors and allow lysis to occur. 
Expression of a  functional MHC  molecule on neurons 
also  induced  a  protracted  disruption  of the  blood-brain 
barrier. This effect may be mediated by soluble CTL prod- 
ucts such as cytokines. Since the effector cells in the adop- 
tive splenocyte transfer have been shown to be virus-spe- 
cific CD8 + (41), the most likely cytokines would be IFN-~/ 
and TNF-oL. Studies to directly test this hypothesis are cur- 
rently underway using IFN-'y and TNF-oe knockout mice. 
Cytokines have recently been shown to cause direct injury 
within the  CNS  in which  injection (45)  or  endogenous 
synthesis (46)  of cytokines resulted in several clinical and 
histopathologic changes within the brain, including blood- 
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brain barrier damage. 
After adoptive transfer of MHC-restricted virus-specific 
CTL  into  mice  whose  neurons  contain  virus  but  lack 
expression of MHC  class  I molecules, clearance occurs by 
60-120 d  (41).  Interestingly, in the model reported here, 
clearance occurs much earlier, by day 15  (Fig. 7).  In both 
instances,  clearance  of virus  from  neurons occurs  in  the 
absence oflysis of these cells, suggesting that intraparenchy- 
real cytokine production may also participate in the clear- 
ance of infectious virus from transgenic brains. Inhibition 
of viral synthesis in the absence of cell death has been doc- 
umented in the CTL response to hepatitis B virus infection 
of hepatocytes  (47-49) and in HIV (50).  In these systems, 
inflammatory cytokines  such  as  IFN-~/  and  TNF-ci  can down-regulate  viral  expression  without  concomitant  cell 
death. 
The stability of the blood-brain barrier is critical to the 
exclusion  of  potentially  neurotoxic  or  cytolytic  blood- 
borne molecules (such as cytokines) from the CNS paren- 
chyma as well as to the maintenance of an appropriate ho- 
meostatic  osmotic  balance  within  the  brain  (51).  While 
rapid alterations in the permeability of the blood-brain bar- 
rier may result in edema and death (52, 53), slower changes 
in permeability need not be life threatening but may lead to 
more  chronic  neurologic  symptoms  (54).  In  agreement 
with this concept, we observed a significant increase in an- 
imal sickness and death at early times after adoptive trans- 
fer, with continued sickness of surviving mice throughout 
the 150-d observation period. 
Several CNS diseases have been associated with transient 
or permanent changes in blood-brain barrier permeability, 
including those associated with CNS infection (54-58), de- 
myelinating diseases  (59),  and  tumors  (60).  Our  study,  in 
which  abnormal  permeability  of the  blood-brain  barrier 
and clinical illness were detected long after virus had been 
cleared from the mice (Fig. 7), indicates that viral infections 
and  CTL-CNS  interactions may induce blood-brain bar- 
rier disruptions and neurologic disease by a  "hit-and-run" 
mechanism,  triggering a  cascade of pathogenic events that 
proceeds in the absence of continual viral stimulation. 
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